Damask — Moscow: Beneficial Cooperation
BIOCAD is the first Russian pharmaceutical manufacturer to obtain marketing authorization for oncology biological drugs in Syria.
The authorization was received for rituximab biosimilar, a drug of monoclonal antibodies, used for treatment of oncohematological disorders (non-Hodgkin’s lymphoma and chronic lymphocytic leukemia.
It should be remarked, that the marketing authorization granted by the Syrian Ministry of Health to the Russian BIOCAD is permanent. It guarantees independency of political situation. That means that within the next five years the product will be supplied to Syria in the volumes exceeding 250 million rubles, according to the most conservative forecasts.
It is of note, that partners of BIOCAD will now be able to take part in the annual state tender in Damask.